

**CONy 2022 Virtual Congress Scientific Program**  
**Program times refer to Central European Time (CET)**

FRIDAY, MARCH 25, 2022		
14:00-16:30	HEADACHE	HALL A
Chair:	<b><u>Dimos Mitsikostas</u></b> , Greece	
14:00-14:50	<b>Do white matter hyperintensities in MRI of migraine patients have clinical significance?</b>	
	<i>Capsule: Diffuse small white matter changes may be present in a proportion of patients with migraine. Whether these changes are more frequent in migraineurs than in non-migraineurs remains controversial. It has been hypothesized that these lesions may be related to migraine progression into a chronic state affecting the sensory processing substantially. Are there clinical implications?</i>	
14:00-14:10	Introduction and Pre-Debate Voting	
14:10-14:25	YES: <b><u>Gisela Terwindt</u></b> , The Netherlands	
14:25-14:40	NO: <b><u>Katharina Eikermann-Haerter</u></b> , USA	
14:40-14:50	Discussion, Rebuttals and Post-Debate Voting	
14:50-15:40	<b>Oral anti-CGRP drugs will displace injectable ones in the prevention of migraine<sup>2</sup></b>	
	<i>Refer to page 29</i>	
	<i>Capsule: Four injectable monoclonal antibodies targeting the CGRP pathway and two oral anti CGRP agents, share good evidence for efficacy and safety in the prevention of migraine. Whether migraineurs will prefer to take an injectable agent monthly or quarterly or an oral agent, remains to be seen.</i>	
14:50-15:00	Introduction and Pre-Debate Voting	
15:00-15:15	YES: <b><u>Sait Ashina</u></b> , USA	
15:15-15:30	NO: <b><u>Uwe Reuter</u></b> , Germany	
15:30-15:40	Discussion, Rebuttals and Post-Debate Voting	
15:40-16:30	<b>Psilocybin will be useful for treating refractory primary headache disorders</b>	
	<i>Capsule: Despite traditional preventive medications, botulinum toxin injections, and newer CGRP blocking agents, successful treatment is elusive for many chronic headache patients. Psilocybin-based compounds may be potential solutions.</i>	
15:40-15:50	Introduction and Pre-Debate Voting	
15:50-16:05	YES: <b><u>Cristina Tassorelli</u></b> , Italy	
16:05-16:20	NO: <b><u>Avi Ashkenazi</u></b> , Israel	
16:20-16:30	Discussion, Rebuttals and Post-Debate Voting	

**CONy 2022 Virtual Congress Scientific Program**  
**Program times refer to Central European Time (CET)**

<b>16:30-18:10</b>	<b>HEADACHE</b>	<b>HALL A</b>
Chair:	<b>Giorgio Lambru</b> , UK	
<b>16:30-17:20</b>	<b>All potential adverse effects to medication should be discussed prior to prescribing<sup>3</sup></b> <i>Refer to page 29</i>	
	<i>Capsule: Ethically, patients have the right to know the risks of treatment, but does this extend to less dangerous or rare potential adverse effects?</i>	
16:30-16:40	Introduction and Pre-Debate Voting	
16:40-16:55	YES: <b>Lars Bendtsen</b> , Denmark	
16:55-17:10	NO: <b>Morris Levin</b> , USA	
17:10-17:20	Discussion, Rebuttals and Post-Debate Voting	
<b>17:20-18:10</b>	<b>The combination of Onabotulinium toxin and CGRP mAb is superior to either agent alone in the prevention of chronic migraine. Yes or No?</b>	
	<i>Capsule: Real world evidence suggests that Botulinum toxin type A is very useful in combination with anti-CGRP mAbs in the prevention of chronic migraine</i>	
17:20-17:30	Introduction and Pre-Debate Voting	
17:30-17:45	YES: <b>Rami Burstein</b> , USA	
17:45-18:00	NO: <b>Hayrunnisa Bolay-Belen</b> , Turkey	
18:00-18:10	Discussion, Rebuttals and Post-Debate Voting	
<b>18:10-19:50</b>	<b>HEADACHE</b>	<b>HALL A</b>
Chair:	<b>Morris Levin</b> , USA	
<b>18:10-19:00</b>	<b>Is the post Covid-19 headache a secondary post infections headache or worsening of preexisting primary headache disorder?</b>	
	<i>Capsule: The reports on neurological findings in COVID-19 infection are increasing rapidly and headache seems to be the leader on the symptom list. Is persistent headache a new post-infectious entity?</i>	
18:10-18:20	Introduction and Pre-Debate Voting	
18:20-18:35	Secondary: <b>Giorgio Lambru</b> , UK	
18:35-18:50	Worsening: <b>Dimos Mitsikostas</b> , Greece	
18:50-19:00	Discussion, Rebuttals and Post-Debate Voting	

**CONy 2022 Virtual Congress Scientific Program**  
**Program times refer to Central European Time (CET)**

19:00-19:50	<b>Do triptans demonstrate better efficacy and/or tolerability than ditans or gepants?</b>
	<i>Capsule: New is not always better and data suggest that ditans and gepants are not more potent than triptans. But have meaningful outcomes and real evidence been considered?</i>
19:00-19:10	Introduction and Pre-Debate Voting
19:10-19:25	YES: <b><u>Patricia Pozo-Rosich</u></b> , Spain
19:25-19:40	NO: <b><u>Bojana Zvan</u></b> , Slovenia
19:40-19:50	Discussion, Rebuttals and Post-Debate Voting